[The treatment of meningococcemia by preserving immune homeostasis].
Lutsik. B D BD
Key Findings
- Meningococcemia, especially with toxic shock, causes major shifts in cellular‑humoral immunity
- Authors propose an immunoregulatory regimen that includes thymalin (or T‑activin) among other agents
- Dosage should be individualized and effectiveness tracked via immunological markers
Practical Outcomes
- For most biohackers, this research offers little direct guidance for longevity or performance. It shows thymalin is being explored in acute infection settings, but no safe, evidence‑based protocol for healthy people is provided.
Summary
The study looked at how the immune system changes in people with severe meningococcal infection and shock, and suggested a mix of drugs—including a peptide called thymalin—to help regulate immunity. The authors say doses should be personalized and monitored with immune tests, but the work is focused on treating a life‑threatening infection, not everyday health or longevity.
Abstract
A study is presented of the cellular-humoral immunity in patients with typical meningococcemia complicated by infectious-toxic shock. Obtained data evidence significant changes of the cellular-humoral immunity in meningococcemias, especially those accompanied by infectious-toxic shock along with traditional methods the authors propose immunoregulatory and pathogenetic treatment: human immunoglobulin, aminocaproic acid, sodium, ethamsilate or dicinon, thymalin or T-activin, dopamin, rifampycin. The dosage of these drugs should be individual. The indications and efficiency should be controlled immunologically.
Study Information
pubmed
1992